Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Prothena
ISIN IE00B91XRN20
|WKN A1KAVV
Market cap (in EUR)
418 m
Country
Ireland
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Ireland
Financials
Key metrics
| Market capitalisation, EUR | 418 m |
| EPS, EUR | -4.72 |
| P/B ratio | 1.6 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 125 m |
| Net income, EUR | -113 m |
| Profit margin | -90.49% |
What ETF is Prothena in?
There is 1 ETF which contains Prothena.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.05% | Equity United States Health Care Biotech | 45 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.